,address1,city,zip,country,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,currency,enterpriseValue,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,financialCurrency,trailingPegRatio
0,14/15 Conduit Street,London,W1S 2XJ,United Kingdom,https://www.tizianalifesciences.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.",9,"{'maxAge': 1, 'name': 'Mr. Gabriele Marco Antonio Cerrone M.B.A.', 'age': 51, 'title': 'Founder, Executive Chairman & Interim CEO', 'yearBorn': 1972, 'fiscalYear': 2023, 'totalPay': 817000, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,1.02,1.02,0.96,1.04,1.02,1.02,0.96,1.04,0.178,-20.199999,268678,268678,257168,260150,260150,0.9651,1.04,100,100,104861232,0.41,1.74,0.9534,0.84245,USD,102537880,63114894,103823000,274933,53735,1728950400,1731628800,0.0026,0.35559,0.01762,0.81,0.0043,103823000,0.018,56.111115,1703980800,1735603200,1719705600,-13728000,-0.13,-0.05,2499:1000,1596153600,-6.495,0.65573776,0.31754446,NCM,EQUITY,TLSA,TLSA,Tiziana Life Sciences Ltd,Tiziana Life Sciences Ltd,1542724200,America/New_York,EST,25281967-9322-3f3e-9012-ef32a973842d,finmb_261234197,-18000000,1.01,none,1130000,0.011,-15788000,179000,0.815,0.854,9.65,-0.69582003,-1.8122799,-199500,-3906000,USD,0
1,14/15 Conduit Street,London,W1S 2XJ,United Kingdom,https://www.tizianalifesciences.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.",9,"{'maxAge': 1, 'name': 'Ms. Keeren  Shah', 'age': 48, 'title': 'COO & CFO', 'yearBorn': 1975, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,1.02,1.02,0.96,1.04,1.02,1.02,0.96,1.04,0.178,-20.199999,268678,268678,257168,260150,260150,0.9651,1.04,100,100,104861232,0.41,1.74,0.9534,0.84245,USD,102537880,63114894,103823000,274933,53735,1728950400,1731628800,0.0026,0.35559,0.01762,0.81,0.0043,103823000,0.018,56.111115,1703980800,1735603200,1719705600,-13728000,-0.13,-0.05,2499:1000,1596153600,-6.495,0.65573776,0.31754446,NCM,EQUITY,TLSA,TLSA,Tiziana Life Sciences Ltd,Tiziana Life Sciences Ltd,1542724200,America/New_York,EST,25281967-9322-3f3e-9012-ef32a973842d,finmb_261234197,-18000000,1.01,none,1130000,0.011,-15788000,179000,0.815,0.854,9.65,-0.69582003,-1.8122799,-199500,-3906000,USD,0
2,14/15 Conduit Street,London,W1S 2XJ,United Kingdom,https://www.tizianalifesciences.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.",9,"{'maxAge': 1, 'name': 'Dr. William A. Clementi Ph.D., Pharm.D.', 'title': 'Chief Development Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,1.02,1.02,0.96,1.04,1.02,1.02,0.96,1.04,0.178,-20.199999,268678,268678,257168,260150,260150,0.9651,1.04,100,100,104861232,0.41,1.74,0.9534,0.84245,USD,102537880,63114894,103823000,274933,53735,1728950400,1731628800,0.0026,0.35559,0.01762,0.81,0.0043,103823000,0.018,56.111115,1703980800,1735603200,1719705600,-13728000,-0.13,-0.05,2499:1000,1596153600,-6.495,0.65573776,0.31754446,NCM,EQUITY,TLSA,TLSA,Tiziana Life Sciences Ltd,Tiziana Life Sciences Ltd,1542724200,America/New_York,EST,25281967-9322-3f3e-9012-ef32a973842d,finmb_261234197,-18000000,1.01,none,1130000,0.011,-15788000,179000,0.815,0.854,9.65,-0.69582003,-1.8122799,-199500,-3906000,USD,0
3,14/15 Conduit Street,London,W1S 2XJ,United Kingdom,https://www.tizianalifesciences.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.",9,"{'maxAge': 1, 'name': 'Dr. Napoleone  Ferrara M.D.', 'age': 66, 'title': 'Member of Scientific Advisory Board', 'yearBorn': 1957, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,1.02,1.02,0.96,1.04,1.02,1.02,0.96,1.04,0.178,-20.199999,268678,268678,257168,260150,260150,0.9651,1.04,100,100,104861232,0.41,1.74,0.9534,0.84245,USD,102537880,63114894,103823000,274933,53735,1728950400,1731628800,0.0026,0.35559,0.01762,0.81,0.0043,103823000,0.018,56.111115,1703980800,1735603200,1719705600,-13728000,-0.13,-0.05,2499:1000,1596153600,-6.495,0.65573776,0.31754446,NCM,EQUITY,TLSA,TLSA,Tiziana Life Sciences Ltd,Tiziana Life Sciences Ltd,1542724200,America/New_York,EST,25281967-9322-3f3e-9012-ef32a973842d,finmb_261234197,-18000000,1.01,none,1130000,0.011,-15788000,179000,0.815,0.854,9.65,-0.69582003,-1.8122799,-199500,-3906000,USD,0
